{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T04:22:55Z","timestamp":1787890975453,"version":"build-2784847793"},"reference-count":22,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2021,11,11]],"date-time":"2021-11-11T00:00:00Z","timestamp":1636588800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30-EY026877"],"award-info":[{"award-number":["P30-EY026877"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Ophthalmology"],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To determine the incidence of ocular adverse effects (AEs) following brolucizumab injection for neovascular age-related macular degeneration at a tertiary academic institution.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Retrospective, single center cohort study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>All patients who received an intravitreal injection of brolucizumab 6\u2005mg for neovascular age-related macular degeneration between October 7, 2019 and July 31, 2020.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Medical records of all patients who received brolucizumab 6\u2005mg during the aforementioned time period were carefully reviewed and all ocular adverse effects after injection were charted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Outcome Measures<\/jats:title>\n                    <jats:p>Incidence of post-injection ocular AEs, including intraocular inflammation (IOI), and time to development of AEs after injection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 77 patients received brolucizumab 6\u2005mg for a total of 115 administrations during the study period. There were 4 AEs (3.5%), including three cases of IOI (2.6%), one central retinal artery occlusion, and one retinal detachment. Two men and two women were affected.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Ocular AEs, including those leading to severe vision loss, may develop after intravitreal brolucizumab 6\u2005mg. A careful discussion of benefits and risks to brolucizumab should be conducted with all patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Precis<\/jats:title>\n                    <jats:p>In this first case series of ocular adverse effects after brolucizumab 6\u2005mg injection at a single tertiary care center, the incidence of ocular adverse effects was 3.5%, including a 2.6% incidence of intraocular inflammation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/11206721211059332","type":"journal-article","created":{"date-parts":[[2021,11,11]],"date-time":"2021-11-11T07:43:20Z","timestamp":1636616600000},"page":"2747-2751","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":19,"title":["Ocular adverse events following intravitreal brolucizumab for neovascular age-related macular degeneration at a single tertiary care center"],"prefix":"10.1177","volume":"32","author":[{"given":"Huy V.","family":"Nguyen","sequence":"first","affiliation":[{"name":"Byers Eye Institute at Stanford, Stanford University School of Medicine, Palo Alto, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0397-2193","authenticated-orcid":false,"given":"Angela S.","family":"Li","sequence":"additional","affiliation":[{"name":"Byers Eye Institute at Stanford, Stanford University School of Medicine, Palo Alto, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amila R.","family":"Silva","sequence":"additional","affiliation":[{"name":"Byers Eye Institute at Stanford, Stanford University School of Medicine, Palo Alto, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8461-3562","authenticated-orcid":false,"given":"Theodore","family":"Leng","sequence":"additional","affiliation":[{"name":"Byers Eye Institute at Stanford, Stanford University School of Medicine, Palo Alto, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2021,11,11]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa054481"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.08.011"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01231-9"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2015.12.030"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.04.017"},{"key":"e_1_3_2_7_2","article-title":"HAWK And HARRIER: 96-week outcomes from the phase 3 trials of brolucizumab for neovascular age-related macular degeneration","author":"Dugel PU","unstructured":"Dugel PU, Singh RP, Koh A, et al. HAWK And HARRIER: 96-week outcomes from the phase 3 trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology 2021 Jan; 128: 89\u201399.","journal-title":"Ophthalmology"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.11.011"},{"key":"e_1_3_2_9_2","article-title":"Clinical characteristics and outcomes of eyes with intraocular inflammation after brolucizumab: post Hoc analysis of HAWK and HARRIER","author":"Singer M","unstructured":"Singer M, Albini TA, Seres A, et al. Clinical characteristics and outcomes of eyes with intraocular inflammation after brolucizumab: post Hoc analysis of HAWK and HARRIER. Ophthalmol Retina 2021 May; 8: S2468-6530(21)00162-7.","journal-title":"Ophthalmol Retina"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2020.100680"},{"key":"e_1_3_2_11_2","article-title":"Retinal vasculitis and intraocular inflammation after intravitreal injection of brolucizumab","author":"Baumal CR","unstructured":"Baumal CR, Spaide RF, Vajzovic L, et al. Retinal vasculitis and intraocular inflammation after intravitreal injection of brolucizumab. Ophthalmology 2020 Oct; 127: 1345\u20131359.","journal-title":"Ophthalmology"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2020.100687"},{"key":"e_1_3_2_13_2","article-title":"[Intraocular inflammation with occlusive retinal vasculitis following intravitreal injection of brolucizumab]","author":"Leclaire MD","year":"2021","unstructured":"Leclaire MD, Lauermann J, Alten F, et al. [Intraocular inflammation with occlusive retinal vasculitis following intravitreal injection of brolucizumab]. Ophthalmologe 2021 Feb 24.","journal-title":"Ophthalmologe"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2020.2810"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1177\/2474126420930863"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10384-021-00818-8"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10384-021-00819-7"},{"key":"e_1_3_2_18_2","unstructured":"Novartis reports one year results of Phase III MERLIN study evaluating Beovu\u00ae every four week dosing and provides update on Beovu clinical program https:\/\/www.novartis.com\/news\/media-releases\/novartis-reports-one-year-results-phase-iii-merlin-study-evaluating-beovu-every-four-week-dosing-and-provides-update-beovu-clinical-program (2021 accessed 1 August 2021)."},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2016.02.046"},{"key":"e_1_3_2_20_2","article-title":"Inflammatory complications of intravitreal anti-VEGF injections","author":"Cox JT","unstructured":"Cox JT, Eliott D, Sobrin L. Inflammatory complications of intravitreal anti-VEGF injections. J Clin Med 2021; 10: 981.","journal-title":"J Clin Med"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2020.100989"},{"key":"e_1_3_2_22_2","article-title":"Brolucizumab and immunogenicity","author":"Sharma A","unstructured":"Sharma A, Kumar N, Parachuri N, et al. Brolucizumab and immunogenicity. Eye (Lond) 2020 Oct; 34: 1726\u20131728.","journal-title":"Eye (Lond)"},{"key":"e_1_3_2_23_2","unstructured":"US Food and Drug Administration. Center for Drug Evaluation and Research https:\/\/www-accessdata-fdagov.laneproxy.stanford.edu\/drugsatfda_docs\/nda\/2019\/761125Orig1s000SumRpdf (25 September 2019)"}],"container-title":["European Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/11206721211059332","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/11206721211059332","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/11206721211059332","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T19:45:21Z","timestamp":1777405521000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/11206721211059332"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,11]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["10.1177\/11206721211059332"],"URL":"https:\/\/doi.org\/10.1177\/11206721211059332","relation":{},"ISSN":["1120-6721","1724-6016"],"issn-type":[{"value":"1120-6721","type":"print"},{"value":"1724-6016","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,11]]}}}